Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

preview_player
Показать описание

  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Dr. Bekaii-Saab on 0:00:56

Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

Dr. Bekaii-Saab Discusses 0:01:21

Dr. Bekaii-Saab Discusses Regorafenib Use in mCRC

Dr. Bekaii-Saab on 0:02:27

Dr. Bekaii-Saab on the ReDOS Study in Metastatic Colorectal Cancer

Dr. Bekaii-Saab on 0:02:26

Dr. Bekaii-Saab on the Impact of Regorafenib in CRC

Dr. Bekaii-Saab on 0:01:23

Dr. Bekaii-Saab on Benefits Associated With Regorafenib or TAS-102 for CRC

Dr. Bekaii-Saab on 0:01:45

Dr. Bekaii-Saab on Moving Metastatic Treatment Strategies to the Adjuvant Setting in CRC

Unpacking the Treatment 0:25:11

Unpacking the Treatment Algorithm of Hepatocellular Carcinoma with Dr. Tanios S. Bekaii-saab

Tanios Bekaii-Saab, MD: 0:00:44

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

MOUNTAINEER Study lead 0:17:40

MOUNTAINEER Study lead to the Tucatinib/Trastuzumab FDA Approval - in discussion w/ Dr. Bekaii-Saab

Tanios Bekaii-Saab, MD: 0:02:02

Tanios Bekaii-Saab, MD: Impact of Third-Line Therapy

Emerging Role of 0:32:21

Emerging Role of HER2-Targeted Therapy in BTCs — Tanios Bekaii-Saab, MD

Early- Versus Late-Onset 0:06:37

Early- Versus Late-Onset Colorectal Cancer

Tanios Bekaii-Saab, MD: 0:01:12

Tanios Bekaii-Saab, MD: Mechanisms of Action in Regorafenib

Dr. Flaherty on 0:01:02

Dr. Flaherty on the Tolerability of Encorafenib/Binimetinib in Melanoma

Dr. Bekaii-Saab Discusses 0:01:32

Dr. Bekaii-Saab Discusses QoL With Regorafenib Dose Escalation in mCRC

Evidence in BRAF-Mutant 0:03:42

Evidence in BRAF-Mutant CRC Tumors

Dr. Bendell on 0:00:42

Dr. Bendell on the Future of Regorafenib for Patients With CRC

Selective Internal Radiation 0:05:13

Selective Internal Radiation Therapy in Colorectal Cancer

Oncology Today with 0:58:45

Oncology Today with Dr Neil Love: Special Edition — What I Tell My Patients About New Treatments ......

Sequencing of Therapy 0:04:26

Sequencing of Therapy in Refractory mCRC

Debate: Optimal first-line 0:08:28

Debate: Optimal first-line therapy in unresectable HCC? - MKI followed by immunotherapy

Debate 10: What 0:12:37

Debate 10: What do we do after FOLFIRINOX? - Gemcitabine is Standard

Colorectal Cancer: Regorafenib 0:05:32

Colorectal Cancer: Regorafenib Patient Selection and Dosing

Recent Advances and 0:59:04

Recent Advances and Future Directions in Breast Cancer — With Dr Harold Burstein and Dr Virginia ......